View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
November 25, 2021

FDA places clinical hold on Selecta Biosciences’ trial of MMA gene therapy

The FDA has sought additional data on the chemistry, manufacturing and controls linked to MMA-101. 

The US Food and Drug Administration (FDA) has issued a clinical hold on Selecta Biosciences’ Phase I/II clinical trial of its gene therapy candidate, SEL-302, to treat individuals with methylmalonic acidemia (MMA).

SEL-302 comprises ImmTOR in combination with MMA-101.

Utilising its proven ImmTOR platform, Selecta develops tolerogenic treatments that specifically alleviate undesirable immune responses.

The FDA notified the company of the clinical hold via a letter, which also sought further data on the chemistry, manufacturing and controls linked to the MMA-101 product candidate.

The letter had no unresolved clinical or pre-clinical issues, adding that the trial has not begun yet.

Furthermore, no human patients would review doses of MMA-101 until all the concerns of the FDA are addressed.

Selecta plans to work collaboratively with the FDA to meet further data requirements.

Selecta Biosciences president and CEO Carsten Brunn said: “Patient safety is our primary concern, and we are committed to addressing the FDA’s questions regarding CMC as expeditiously as possible.

“We look forward to working closely with the FDA to satisfy all outstanding concerns, and to providing additional updates early next year.”

In April 2021, Selecta and Asklepios BioPharmaceutical updated their partnership to assess MMA-101 plus ImmTOR for MMA treatment.

According to the collaboration, Selecta gained complete rights to the MMA programme and will advance the combination therapy clinically.

A rare metabolic ailment, MMA interferes with the ability of the body to metabolise specific amino acids and fats.

The disease is expected to cause hyperammonemia, metabolic acidosis and long-term consequences such as feeding issues, developmental delays, intellectual incapability and chronic kidney disease.

The latest development comes after the FDA put a partial clinical hold on Kura Oncology’s Phase Ib KOMET-001 trial of KO-539 in patients with acute myeloid leukaemia.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena